Proteome Sciences presented data this week at the Alzheimer's Association International Conference in Boston demonstrating that treatment with its casein kinase 1 delta inhibitor compounds improved cognition in a mouse model of tauopathy.

The company also demonstrated that treatment with the compounds leads to a reduction of tau deposits and tau phosphorylation in these mouse models, marking a step forward for its CK1d inhibitor program in Alzheimer's.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.